WebAbstract. Purpose: In general, 50 % up to 80 % of metastasized germ cell tumor patients can be cured by platinum-based chemotherapy. However, 3-5 % of patients will still die of … WebApr 30, 2024 · Approaching Platinum-Refractory Recurrent Ovarian Cancer. Apr 30, 2024. ... This is a patient though that actually although she has no persistent disease at the completion of primary therapy, which would be kind of the standard definition of refractory, ...

Phase 2 study of canfosfamide in combination with pegylated …

WebMar 22, 2024 · However, those with primary platinum-refractory disease were excluded. The primary end point of the study was confirmed objective response rate (ORR) as assessed by investigators with a key secondary end point of duration of response (DOR). ORR was also assessed by a blinded independent central review (BICR). WebMar 3, 2024 · PIT-565 is under clinical development by Novartis and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PIT-565’s ... phytofactories

Understanding Recurrent or Progressive Ovarian Cancer - Clearity Foun…

Web19 hours ago · In the population with platinum-refractory disease, the TIA-GEP score was balanced between arms; however, in the population with platinum-eligible disease, there was an imbalance in TIA-GEP scores, with a higher proportion of patients with a TIA-GEP score of 10 or higher in the nivolumab arm (47.5%) versus the nivolumab plus ipilimumab arm … WebSep 26, 2024 · Patients with primary platinum-refractory disease as defined by those who progressed during or within four weeks of completion of first platinum-based … Web•Patietnts with primary platinum-refractory disease (defined as progression during or within 4 weeks after completion of the first platinum regimen) are not eligible. • EOG of 0 to 1. • … phyto factory